1. Home
  2. LYRA vs LUCY Comparison

LYRA vs LUCY Comparison

Compare LYRA & LUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • LUCY
  • Stock Information
  • Founded
  • LYRA 2005
  • LUCY 2017
  • Country
  • LYRA United States
  • LUCY United States
  • Employees
  • LYRA N/A
  • LUCY N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • LUCY Ophthalmic Goods
  • Sector
  • LYRA Health Care
  • LUCY Health Care
  • Exchange
  • LYRA Nasdaq
  • LUCY Nasdaq
  • Market Cap
  • LYRA 15.0M
  • LUCY 8.9M
  • IPO Year
  • LYRA 2020
  • LUCY 2022
  • Fundamental
  • Price
  • LYRA $9.15
  • LUCY $2.14
  • Analyst Decision
  • LYRA Buy
  • LUCY
  • Analyst Count
  • LYRA 2
  • LUCY 0
  • Target Price
  • LYRA $16.00
  • LUCY N/A
  • AVG Volume (30 Days)
  • LYRA 288.0K
  • LUCY 5.9M
  • Earning Date
  • LYRA 08-13-2025
  • LUCY 08-11-2025
  • Dividend Yield
  • LYRA N/A
  • LUCY N/A
  • EPS Growth
  • LYRA N/A
  • LUCY N/A
  • EPS
  • LYRA N/A
  • LUCY N/A
  • Revenue
  • LYRA $1,185,000.00
  • LUCY $1,707,470.00
  • Revenue This Year
  • LYRA N/A
  • LUCY $367.48
  • Revenue Next Year
  • LYRA $1,286.17
  • LUCY $166.67
  • P/E Ratio
  • LYRA N/A
  • LUCY N/A
  • Revenue Growth
  • LYRA N/A
  • LUCY 22.75
  • 52 Week Low
  • LYRA $3.81
  • LUCY $1.57
  • 52 Week High
  • LYRA $37.50
  • LUCY $11.16
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 44.26
  • LUCY 42.95
  • Support Level
  • LYRA $8.35
  • LUCY $1.95
  • Resistance Level
  • LYRA $9.36
  • LUCY $2.20
  • Average True Range (ATR)
  • LYRA 1.25
  • LUCY 0.34
  • MACD
  • LYRA -0.72
  • LUCY -0.05
  • Stochastic Oscillator
  • LYRA 9.95
  • LUCY 5.12

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.

Share on Social Networks: